Skip to content

Clinical study of the effect of different intravenous general anesthetic drugs (propofol, etomidate, and ciprofol) on cerebral blood flow rate during induction of anesthesia

Clinical study of the effect of different intravenous general anesthetic drugs (propofol, etomidate, and ciprofol) on cerebral blood flow rate during induction of anesthesia

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073807
Enrollment
Unknown
Registered
2023-07-21
Start date
2023-07-19
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical study of the effect of different intravenous general anesthetic drugs (propofol, etomidate, and ciprofol) on cerebral blood flow rate during induction of anesthesia

Interventions

Propofol group(groupP):None
Etomidate group (Group E):None
Ciprofol group (Group C):None

Sponsors

The Seventh Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years and =65 years; 2.ASA grade I to II; 3. Patients undergoing elective surgery requiring tracheal intubation and general anesthesia; 4. Be willing to accept research and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous neurological diseases, acute intracranial lesions (intracranial infection, brain trauma, stroke, cerebral hemorrhage), cerebrovascular diseases, and inability to use transcranial Doppler; 2. Pregnant women, lactation, emergency surgery, language disorders, intellectual impairment, dementia and mental disorders; 3. Allergic history to experimental drugs (propofol, etomidate, ciprofol, ephedrine, etc.). 4. Patients with ASA grade =III; 5. Alcohol or drug abusers; 6. Patients who are receiving antihypertensive drugs, sedatives, analgesics and psychotropic drugs; 7. Morbidly obese (BMI> 40); 8. age 65 years old; 9. Patient refuses. 10. Cardiovascular diseases (hypertension, symptomatic ischemic heart disease, etc.), diabetes mellitus.

Design outcomes

Primary

MeasureTime frame
Mean middle cerebral artery blood flow velocity before intubation (T4) 3 min after induction;

Secondary

MeasureTime frame
Mean arterial pressure ;Total phenylephrine dosage ;Time to loss of eyelash reflex (time from start of administration to loss of eyelash reflex);Middle cerebral artery flow rate in other periods:Before induction of anesthesia (T0,pre-oxygenation, baseline value), before induction of anesthesia (T1,pre-oxygenation before medication), and 1min (T2), 2min (T3), 3min (T4), 5min (T5), 10min (T6), 15min (T7) after induction of anesthesia;Systolic cerebral blood flow velocity ;diastolic cerebral blood flow velocity;pulsatility index (PI);resistance index (RI);Total atropine consumption;

Countries

China

Contacts

Public ContactChi XinJin

The Seventh Affiliated Hospital, Sun Yat-sen University

chixinjin@sysush.com+86 139 0301 0076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026